Marc Loriaux
OHSU Knight Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Marc Loriaux as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01620216 · Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaOHSU Knight Cancer Institute · terminated · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Phase II proof-of-concept trial to study kinase inhibition in relapsed/refractoR21CA159265 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · fiscal years 2011 to 2012 · $272,667 awarded in 2012Grant number is on one of their registry trials
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in childhood acute lymphoblastic leukemia.